The latest treatment for chronic obstructive pulmonary disease-Targeted Lung Denervation Ablation TLD. Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable chronic airway disease characterized by persistent airflow limitation and corresponding respiratory symptoms; its pathological changes are mainly airway and/or alveolar abnormalities. Targeted Lung Denervation TLD is a procedure that targets the parasympathetic nerves and blocks their innervation to achieve a permanent anticholinergic effect (the effect is similar to that of anticholinergic drugs, the mechanism of which – acetylcholine released from the parasympathetic nerve endings – can cause contraction of the bronchial smooth muscle. Anticholinergic drugs dilate airway smooth muscle by blocking this type of receptor, improving airflow limitation and symptoms of chronic obstructive pulmonary disease. This treatment is a simple in-office bronchoscopic procedure that reduces the clinical consequences of neural hyperactivity. If TLD therapy is required, standardize the treatment in strict compliance with medical advice.